Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP) The study size was expanded to 183 participants due to patient and ...
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Apollo Therapeutics, the portfolio biopharmaceutical company, today announces positive results from its 32-week CHAMELEON phase 2a clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results